Company profile
BEYOND AIR, INC.
NASDAQ:XAIRMedical/Dental Instruments
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| NITRIC OXIDE | phase3 | — | 5 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05351502 | phase1 | unknown | 2022-08-14 | 2025-05-30 | Beyond Air Inc. | A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors |
| NCT04060979 | phase2 | completed | 2019-11-06 | 2020-03-02 | Beyond Air Inc. | Evaluation of Two Doses of Nitric Oxide (NO) Given Intermittently Via Inhalation to Subjects With Bronchiolitis |
| NCT03053388 | phase3 | completed | 2017-03-05 | 2018-04-28 | Beyond Air Inc. | Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis |
| NCT01958944 | phase1_2 | completed | 2013-12-01 | 2015-11-01 | Beyond Air Inc. | Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis |
| NCT01768884 | phase1_2 | completed | 2013-01-01 | 2016-01-01 | Beyond Air Inc. | Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation to Subjects With Bronchiolitis |
FDA applications (0)
No records yet.